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Abstract
Background: High serum levels of estradiol are associated with increased risk of postmenopausal breast cancer.
Little is known about the gene expression in normal breast tissue in relation to levels of circulating serum estradiol.
Methods: We compared whole genome expression data of breast tissue samples with serum hormone levels using
data from 79 healthy women and 64 breast cancer patients. Significance analysis of microarrays (SAM) was used to
identify differentially expressed genes and multivariate linear regression was used to identify independent associations.
Results: Six genes (SCGB3A1, RSPO1, TLN2, SLITRK4, DCLK1, PTGS1) were found differentially expressed according to
serum estradiol levels (FDR = 0). Three of these independently predicted estradiol levels in a multivariate model, as
SCGB3A1 (HIN1)a n dTLN2 were up-regulated and PTGS1 (COX1) was down-regulated in breast samples from women
with high serum estradiol. Serum estradiol, but none of the differentially expressed genes were significantly associated
with mammographic density, another strong breast cancer risk factor. In breast carcinomas, expression of GREB1 and
AREG was associated with serum estradiol in all cancers and in the subgroup of estrogen receptor positive cases.
Conclusions: We have identified genes associated with serum estradiol levels in normal breast tissue and in breast
carcinomas. SCGB3A1 is a suggested tumor suppressor gene that inhibits cell growth and invasion and is methylated
and down-regulated in many epithelial cancers. Our findings indicate this gene as an important inhibitor of breast cell
proliferation in healthy women with high estradiol levels. In the breast, this gene is expressed in luminal cells only and
is methylated in non-BRCA-related breast cancers. The possibility of a carcinogenic contribution of silencing of this gene
for luminal, but not basal-like cancers should be further explored. PTGS1 induces prostaglandin E2 (PGE2) production
which in turn stimulates aromatase expression and hence increases the local production of estradiol. This is the first
report studying such associations in normal breast tissue in humans.
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Background
Influence of estradiol on breast development [1], the
menopausal transition [2] and on the breast epithelial
cells [3] is widely studied. However, little is known
about the effect of serum estradiol on gene expression
in the normal breast tissue. For postmenopausal women,
high serum estradiol levels are associated with increased
risk of breast cancer [4-6]. The results are less conclu-
sive for premenopausal women, but epidemiologic evi-
dence indicates an increased risk from higher exposure
to female hormones [7].
In estrogen receptor (ER) positive breast carcinomas,
the proliferating tumor cells express ER while in normal
breast tissue the proliferating epithelial cells are ER
negative (ER-) [8,9]. Both normal and malignant breast
epithelial cells are influenced by estradiol but through
different mechanisms. In the lack of ER, normal breast
epithelial cells receive proliferating paracrine signals
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stimuli in the proliferation of ER+ breast cancer cells is
evident from the effect of anti-estrogen treatment. Pre-
viously, several studies have identified genes whose
expression is regulated by estradiol in breast cancer cell
lines. Recently, a study reported an association between
serum levels of estradiol and gene expression of trefoil
factor 1 (TFF1), growth regulation by estrogen in breast
cancer 1 (GREB1), PDZ domain containing 1 (PDZK1)
and progesterone receptor (PGR) in ER+ breast carcino-
mas [10]. Functional studies on breast cancer cell lines
have described that estradiol induces expression of c-fos
[11] and that exposure to physiologic doses of estradiol
is necessary for malignant transformation [12]. Intratu-
moral levels of estrogens have also been measured and
were found correlated with tumor gene expression of
estradiol-metabolizing enzymes and the estrogen recep-
tor gene (ESR1) [13] and of proliferation markers [14].
A recent study did, however, conclude that the intratu-
moral estradiol levels were mainly determined by its
binding to ER (associated with ESR1-expression). The
intratumoral estradiol levels were not found to be asso-
ciated with local estradiol production [15]. Serum estra-
diol levels were found to be associated with local
estradiol levels in normal breast tissue of breast cancer
patients in a recent study [16]. This strengthens the
hypothesis that serum estradiol levels influence the gene
expression in breast tissue.
Wilson and colleagues studied the effect of estradiol
on normal human breast tissue transplanted into athy-
mic nude mice. They identified a list of genes associated
with estradiol treatment, including TFF1, AREG,
SCGB2A2, GREB1 and GATA3. The normal tissues used
in the xenografts were from breasts with benign breast
disease and from mammoplasty reductions [17].
Studies describing associations between serum estra-
diol levels and gene expression of normal human breast
tissue in its natural milieu are lacking. Knowledge about
gene expression changes associated with high serum
estradiol may reveal biological mechanisms underlying
the increased risk for both elevated mammographic den-
sity and for developing breast cancer as seen in women
with high estradiol levels. We have identified genes dif-
ferentially expressed between normal breast tissue sam-
ples according to serum estradiol levels. Several genes
identified in previous studies using normal breast tissue
or breast carcinomas are confirmed, but additional
genes were identified making important contributions to
our previous knowledge.
Methods
Subjects
Two cohorts of women were recruited to the study from
different breast diagnostic centers in Norway in the
period 2002-2007 as described previously [18]. Exclusion
criteria were pregnancy and use of anticoagulant ther-
apy. The first cohort consisted of 120 women referred
to the breast diagnostic centers who were cancer-free
after further evaluation. These will be referred to as
healthy women. Breast biopsies were taken from an area
with some mammographic density in the breast contral-
ateral to any suspect lesion. The second cohort con-
sisted of 66 women who were diagnosed with breast
cancer. For this cohort, study biopsies were taken from
the breast carcinoma after the diagnostic biopsies were
obtained. Fourteen gauge needles were used for the
biopsies and sampling was guided by ultrasound. The
biopsies were either soaked in RNAlater (Ambion, Aus-
tin, TX) and sent to the OsloU n i v e r s i t yH o s p i t a l ,
Radiumhospitalet, before storage at -20°C or directly
s n a p - f r o z e ni nl i q u i dn i t r o g e na n ds t o r e da t- 8 0 ° C .
Based on serum hormone analyses (see below), 57 of the
120 healthy women included were postmenopausal, 43
were premenopausal, 10 were perimenopausal and
serum samples were lacking for 10 women. Of the 66
breast cancer patients, 50 were estimated to be postme-
nopausal, 13 to be premenopausal and 3 to be perime-
nopausal. All women provided information about height,
weight, parity, hormone therapy use and family history
of breast cancer and provided a signed informed con-
sent. The study was approved by the regional ethical
committee (IRB approval no S-02036).
Three additional datasets were used to explore the
regulation of identified genes in breast cancer. One
unpublished dataset from the Akershus University Hos-
pital (AHUS), Norway, included normal breast tissue
from 42 reduction mammoplasties and both tumor and
normal adjacent tissue from 48 breast cancer patients
(referred to as the AHUS dataset). Another unpublished
dataset from University of North Carolina (UNC), USA,
included breast cancer and adjacent normal breast tissue
from 55 breast cancer patients (referred to as the UNC
dataset). The third dataset is previously published and
consists of biopsies from 31 pure ductal carcinoma in
situ (DCIS), 36 pure invasive breast cancers and 42
tumours with mixed histology, both DCIS and invasive
[19].
Serum hormone analysis
Serum hormone levels (LH, FSH, prolactin, estradiol,
progesterone, SHBG and testosterone) were measured
with electrochemiluminescence immunoassays (ECLIA)
on a Roche Modular E instrument (Roche, Basel, Swit-
zerland) by Department of Medical Biochemistry, Oslo
University Hospital, Rikshospitalet. The menopausal sta-
tus was determined based on serum levels of hormones,
age and hormone use. The criteria used can be found in
Additional file 1. Biochemically perimenopausal women
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excluded from analyses stratified on menopause. These
hormone assays are tested through an external quality
assessment scheme, Labquality, and the laboratory is
accredited according to ISO-ES 17025. Serum estradiol
values are given as picograms per milliliter (pg/ml) (pg/
ml × 3.67 = pmol/). The functional sensitivity of the
estradiol assay was 10.9 pg/ml (40 pmol/l) with a total
analytical sensitivity of < 5%.
Gene expression analysis
RNA extraction and hybridization were performed as
previously described [18]. Briefly, RNeasy Mini Protocol
(Qiagen, Valencia, CA) wasu s e df o rR N Ae x t r a c t i o n .
Forty samples (38 from healthy women) were excluded
from further analysis due to low RNA amount (< 10 ng)
or poor RNA quality assessed by the curves given by
Agilent Bioanalyzer (Agilent Technologies, Palo Alto,
CA). The analyses were performed before RNA integrity
value (RIN) was included as a measure of degradation
and samples with poor quality were excluded. Agilent
Low RNA input Fluorescent Linear Amplification Kit
Protocol was used for amplification and labelling with
Cy5 (Amersham Biosciences, Little Chalfont, England)
for sample RNA and Cy3 (Amersham Biosciences, Little
Chalfont, England) for the reference (Universal Human
total RNA (Stratagene, La Jolla, CA)). Labelled RNA was
hybridized onto Agilent Human Whole Genome Oligo
Microarrays (G4110A) (Agilent Technologies, Santa
Clara, CA). Three arrays were excluded due to poor
quality leaving data from 79 healthy women and 64
breast cancer patients.
The scanned data was processed in Feature Extraction
9.1.3.1 (Agilent Technologies, Santa Clara, CA). Locally
weighted scatterplot smoothing (lowess) was used to
normalize the data. The normalized and log2-trans-
formed data was stored in the Stanford Microarray
Database (SMD)[20] and retrieved for further analysis.
Gene filtering excluded probes with ≥ 20% missing
values and probes with less than three arrays being at
least 1.6 standard deviation away from the mean. This
reduced the dataset from 40791 probes to 9767 for the
healthy women and to 10153 for the breast cancer
patients. Missing values were imputed in R using the
method impute. knn in the library impute [21]. All
expression data are available in Gene Expression Omni-
bus (GEO)(GSE18672).
Mammographic density
Mammographic density was estimated from digitized
craniocaudal mammograms as previously described [18]
using the University of Southern California Madena
assessment method [22]. First, the total breast area was
outlined using a computerized tool and the area was
represented as number of pixels. One of the co-authors,
GU, identified a region of interest that incorporated all
areas of density excluding those representing the pector-
alis muscle and scanning artifacts. All densities above a
certain threshold were tinted yellow, and the tinted
pixles converted to cm
2 representing the absolute den-
sity and was available for 108 of 120 healthy women.
Percent mammographic density is calculated as the
absolute density divided by the total breast area and was
available for 114 of 120 healthy women. Test-retest
reliability was 0.99 for absolute density.
Statistical Analysis
Quantitative significance analysis of microarrays (SAM)
[23,24] was used for analysis of differentially expressed
genes, by the library samr in R 2.12.0. Serum estradiol
(nmol/L) was used as dependent variable. The distribu-
tion of serum levels is skewed and therefore the non-
parametric Wilcoxon test-statistic was used. Probes with
an FDR < 50% were included for gene ontology analyses.
DAVID Bioinformatics Resources 2008 from the
National Institute of Allergy and Infectious Diseases, NIH
[25] was used for gene ontology analysis. Functional anno-
tation clustering was applied and the following annotation
categories were selected: biological processes, molecular
function, cellular compartment and KEGG pathways. We
included annotation terms with a p-value (FDR-corrected)
of < 0.01 containing between 5 and 500 genes.
For multivariate analysis, linear regression was fitted
in R 2.12.0 to identify independent associations. Step-
wise selection was performed to determine which vari-
ables had an independent contribution to the response
variable. In the first step, all variables were included in
the model. The variable with the highest p-value was
rejected from the model in each step, before the model
was refitted. This was repeated until all variables in the
model had a p-value smaller than 0.05.
Linear regression was used to determine the indepen-
dent association between serum estradiol and the differ-
entially expressed genes in healthy women. Age,
menopause and current hormone use were included in
the model and forced to stay throughout the stepwise
selection to correct for confounding by these factors.
Linear regression was also fitted in two analyses with
mammographic density in healthy women as a depen-
dent variable. In one set of analyses serum hormone
levels were included as the independent covariates, and
in the other analysis, variables representing gene expres-
sion associated with serum estradiol were included as
covariates. Epidemiologic covariates, such as age, BMI,
parity and use of hormone therapy were included in the
mammographic density analyses and forced to stay
throughout the stepwise selection to control for poten-
tial confounding by these factors.
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subtypes published by Sørlie et al in 2001 [26]. The
total gene set was filtered for the intrinsic genes. The
correlation between gene expression profiles for the
intrinsic genes for each sample with each subtype was
calculated. Each sample was assigned to the subtype
with which it had the highest correlation. Samples with
all correlations < 0.1 were not assigned to any subtype.
Two-sided t-tests were used to check for difference in
expression for single genes between two categories of
variables (eg: pre- and postmenopausal).
Results
Gene expression in normal breast tissue according to
serum estradiol levels
Genes differentially expressed in normal breast tissue
from healthy women according to serum estradiol levels
with FDR = 0 are listed in Table 1. The gene ontology
terms extracellular region and skeletal system develop-
ment were significantly enriched in the top 80 up-regu-
lated genes (FDR < 50%). There were no significant gene
ontology terms enriched in the down-regulated genes
with FDR < 50 (n = 8), although response to steroid hor-
mone stimulus was the most enriched term with three
observed genes (prostaglandin-endoperoxide synthase 1
(PTGS1), ESR1 and GATA3)(Additional file 2).
The genes differentially expressed in normal breast tis-
sue according to serum estradiol with an FDR = 0 (from
Table 1) were tested for differential expression between
breast cancer tissue and normal breast tissue from
healthy women. All six genes were differentially
expressed between carcinomas and normal tissue. Inter-
estingly, the expression in breast carcinomas was similar
to that in normal tissue from women with lower levels
of circulating estradiol and opposite to that found in
normal samples from women with higher levels of
serum estradiol (Table 1). Comparing the expression of
these genes in normal breast tissue with the expression
in ER+ and ER- carcinomas respectively revealed similar
results (Table 1).
In tumors, SCGB3A1 tended to be expressed at a
lower level in basal-like tumors compared with all other
tumors or compared with luminal A tumors, but this
did not reach statistical significance (both p-values =
0.2). However in two other datasets (AHUS and UNC),
SCGB3A1 was expressed at significantly lower levels in
basal-like tumors compared with all other subtypes (p =
0.04 and 0.003 respectively). There was no consistent
significant difference in SCGB3A1 expression in ER+
and ER- tumors.
Of the six genes differentially expressed according to
serum estradiol in normal breast tissue, three were
Table 1 Genes significantly differentially expressed in normal breast tissue of healthy women according to serum
estradiol.
Gene Name SCGB3A1 SLITRK4 TLN2 DCLK1 RSPO1 PTGS1
A Chromosomal location of the gene 5q35.3 Xq27.3 15q15-q21 13q13 1p34.3 9q32-q33.3
q-value (%) SAM
1) 0000 0 0
Gene expression in high s-est
2)
(compared with low s-est) up up up up up down
B BC
3) vs normal breast tissue (p-value)
4) 5.00E-15 1.50E-03 2.60E-04 6.00E-04 4.90E-12 0.02
Gene expression n BC
3)
(compared with normal tissue) down down down down down up
ER+ BC vs normal tissue
5) 4) 2.20E-13 0.01 1.30E-03 4.20E-03 3.30E-12 0.05
Gene expression in ER+ BC
(compared with normal tissue) down down down down down up
ER- BC vs normal tissue
6) 4) 1.10E-04 0.03 0.01 0.01 0.02 0.05
Gene expression in ER- BC
(compared with normal tissue) down down down down down up
Invasive BC vs DCIS
3) 4) 0.04 0.12 0.01 0.66 0.24 0.001
Gene expression in invasive BC
(compared with DCIS) down - up - - up
A) Q-values and regulation of gene expression from quantitative SAM analysis of gene expression according to serum estradiol. B) Significance testing of
difference in gene expression of the genes identified in A) in different sample cohorts.
1) Q-value from SAM of gene expression in normal breast tissue according to serum estradiol
2) s-est = serum estradiol
3) BC = breast cancer
4) P-value from two-sided t-test
5) ER+ BC = estrogen recepor positive breast cancer (n = 53)
6) ER- BC = estrogen recepor negative breast cancer (n = 8)
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breast carcinomas based on a previously published data-
set [19](Table 1). SCGB3A1 was down-regulated in inva-
sive compared with DCIS, whereas talin 2 (TLN2) and
PTGS1 were up-regulated in invasive compared with
DCIS.
A linear regression was fitted with all differentially
expressed genes as covariates and controlling for age,
menopause and current hormone therapy use. After leave-
one-out elimination of insignificant covariates, SCGB3A1,
TLN2 and PTGS1 were still significant (Table 2).
Serum estradiol related to mammographic density in
healthy women
Regression analysis in postmenopausal women showed
that serum estradiol was independently associated with
both absolute and percent mammographic density when
controlling for age, BMI and current use of hormone
therapy (Table 3). None of the genes differentially
expressed in normal breast tissue according to serum
estradiol levels were independently associated with
mammographic density (data not shown).
Gene expression in breast carcinomas according to serum
estradiol levels
In breast carcinomas, quantitative SAM revealed two
genes, AREG and GREB1, as differentially expressed
according to serum estradiol levels with FDR = 0 (Table
4). Both genes were up-regulated in samples from
women with high serum estradiol (estradiol was used as
a continuous response variable in the analysis). Of 16
probes up-regulated in samples from women with high
serum estradiol, there were three probes for TFF3 and
one for TFF1, although these did not reach statistical
significance (Table 4). No genes were significantly
down-regulated according to serum estradiol. In ER+
samples (n = 53), we also found AREG and GREB1 up-
regulated in samples from women with high serum
estradiol (FDR = 0), but the TFF-genes were not up-
regulated. Among the ER- samples (n = 8) there was
very little variation in serum estradiol levels and a
Table 2 Genes independently associated with serum
estradiol in a linear regression model.
Covariate Estimate
1) Std error p-value
SCGB3A1 0.068 0.025 0.009
TLN2 0.142 0.061 0.024
PTGS1 -0.145 0.066 0.030
SLITRK4 0.086 0.075 0.25
2)
RSPO1 0.045 0.045 0.32
2)
DCLK1 0.023 0.063 0.71
2)
All genes differentially expressed according to serum estradiol (Table 1) were
included. Values shown are corrected for age, menopause and current
hormone therapy. After leave-one-out stepwise selection the following
covariates remained:
1) Estimate denotes the beta-value corresponding to each covariate in the
regression equation.
2) Values for the non-significant genes are from the last model before they
were excluded.
Table 3 Serum hormones independently associated with
mammographic density in linear regression models.
Absolute density Percent density
Covariate Estimate
1) p-value Estimate p-value
Parity -8.18 0.01 - -
Serum estradiol 95.55 7.1E-05 51.31 9.3E-03
Values shown are corrected for age, HT and BMI. Through leave-one-out
stepwise elimination of covariates, prolactin, SHBG and testosterone were
excluded and the following variables remained.
1) Estimate denotes the beta-value corresponding to each covariate in the
regression equation.
Table 4 Genes significantly differentially expressed
according to serum estradiol levels in breast carcinomas.
Gene Name AREG GREB1 TFF3
7) TFF3
7) TFF1
A Chromosomal location 4q13-
21
2p25.1 21q22.3 21q22.3 21q22.3
q-value (%) SAM all
tumors
1)
0 0 20.5 20.5 20.5
Gene expression in
high s-est
(compared with low s-
est)
2)
up up up up up
q-value (%) SAM ER+
BC
1)3)
00 - - -
Gene expression in
high s-est
(compared with low s-
est)
2)
up up - - -
B BC
4) vs normal breast
tissue
5
0.38 0.18 4.80E-
05
2.60E-
04
1.20E-
07
Gene expression in
BC
4)
(compared with
normal)
- - up up up
ER+ vs ER- BC
4) 5 0.08 4.80E-
08
2.00E-
06
2.40E-
07
0.002
Gene expression in ER+
BC
(compared with ER-
BC
6))
up up up up up
A) Quantitativ SAM analysis for differential expression according to serum
estradiol with q-values and direction of regulation indicated. B) Significance
testing of difference in gene expression of the genes identified in A) in
different sample cohorts.
1) Q-value from SAM of gene expression according to serum estradiol
2) Gene expression in samples from patients with high compared with low
serum estradiol
3) ER+ BC = Estrogen receptor positive breast cancer (n = 53)
4) BC = breast cancer
5) P-value from two-sided t-test
6) ER- BC = Estrogen receptor negative breast cancer (n = 8)
7) Two different probes for TFF3 are used
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serum estradiol is not feasible.
Looking at the expression of these genes in normal
breast tissue from healthy women according to serum
estradiol, both AREG and GREB1 are up-regulated in
samples from women with high estradiol levels without
reaching significance. Comparing the expression of these
genes in breast carcinomas and normal breast tissue,
neither AREG nor GREB1 are differentially expressed
between normal breast tissue and breast carcinomas. All
the probes for TFF-genes are, however, significantly
down-regulated in normal breast tissue compared with
breast carcinomas. All these genes (AREG, GREB1, TFF1
and TFF3) were up-regulated in ER+ carcinomas com-
pared to ER- carcinomas (AREG was only borderline
significant) (Additional file 3).
Discussion
Gene expression in normal breast tissue according to
serum estradiol levels
We have identified genes differentially expressed accord-
ing to serum estradiol in normal breast tissue of healthy
women.
The genes up-regulated in normal breast tissue under
influence of high serum estradiol are enriched for the
gene ontology terms extracellular matrix and skeletal
system development.B o t hE Ri s o f o r m sa and b are
expressed in the stromal cells [27]. The proliferating
epithelial cells are not found to be ER a + [8] and most
often negative to both ER isoforms [9]. In normal breast
tissue, the estrogen-induced epithelial proliferation is, at
least partly, caused by paracrine signals from ER+ fibro-
b l a s t s[ 3 ] .T h ee n r i c h m e n to fg e n eo n t o l o g yt e r m s
related to extracellular matrix may be linked to the
effect of estradiol on the ER+ stromal cells.
Three genes were independently associated with
serum estradiol levels in normal breast tissue in a linear
regression model after controlling for age, menopause
and current hormone therapy. The two genes SCBG3A1
and TLN2 were positively associated with serum estra-
diol and PTGS1 (COX1) negatively.
SCBG3A1 is also called high in normal 1 (HIN1) and
is a secretoglobin transcribed in luminal, but not in
myoepithelial breast cells and is secreted from the cell
[28]. The protein is a tumor suppressor and inhibits cell
growth, migration and invasion acting through the
AKT-pathway. SCBG3A1 inhibits Akt-phosphorylation,
which reduces the Akt-function in promoting cell cycle
progression (transition from the G1 to the S-phase) and
preventing apoptosis (through inhibition of the TGFb-
pathway) [29] (Figure 1).
The SCBG3A1 promoter was found to be hypermethy-
lated with down-regulated expression of the gene in
breast carcinomas compared with normal breast tissue,
w h e r ei ti sr e f e r r e dt oa s“high in normal 1” (HIN1)
[30-32]. Interestingly, theg e n ei sn o tm e t h y l a t e di n
BRCA-mutated and BRCA-like breast cancer [32].
Methylation of the gene is suggested to be an early
event in non-BRCA-associated breast cancer [33].
We found SCBG3A1 down-regulated in basal-like can-
cers compared to other subtypes. At first glance, this
may seem contradictory to the observation that the gene
is not methylated in BRCA-like breast cancers. However,
Krop and colleagues found that the gene is expressed in
luminal epithelial cell lines, but not in myoepithelial cell
lines. The reduced expression seen in basal-like cancer
could be due to a myoepithelial phenotype arising from
a myoepithelial cell of origin or from phenotypic
changes acquired during carcinogensis. This could also
be linked to the lack of methylation in BRCA-associated
breast cancers, which are often basal-like. An a priori
low gene expression would make methylation unneces-
sary. The increased Akt-activity seen in basal-like can-
cers [34] is consistent with the low levels of SCBG3A1
expression observed in the basal-like cancers in this
study leading to increased Akt-phosphorylation and
thereby Akt-activity.
The up-regulation of SCGB3A1 in the breasts of
women with high serum estradiol protects the breast
epithelial cells against uncontrolled proliferation.
Women with methylation of the SCGB3A1-promoter
may be at risk of developing luminal, but not basal-like,
breast cancer and a reduction in serum estradiol levels
may be protective for these women. Hormone therapy
after menopause is associated with receptor positive, but
not receptor negative, breast cancer [35]. Our results
indicate that the same may be true for circulating estra-
diol levels in absence of functional SCGB3A1, but this is
not yet shown empirically.
PTGS1 (prostaglandin-endoperoxide synthase 1) is
synonymous with cyclooxygenase 1 (COX1)a n dc o d e s
for an enzyme important in prostaglandin production.
Studies of normal human adiopocytes have shown that
the enzyme induces production of prostaglandin E2
(PGE2) which in turn increases the expression of aroma-
tase (CYP19A1) [36]. Aromatase is the enzyme responsi-
ble for the last step in the conversion of androgens to
estrogens in adipose tissue. Hence, the expression of
PTGS1 may increase the local production of estradiol
(Figure 2). In normal breast tissue, we observed that the
expression of PTGS1 was lower in samples from women
with higher levels of serum estradiol. This may be due
to negative feedback. High systemic levels of estradiol
make local production unnecessary and PTGS1-induced
aromatase production is abolished.
The up-regulation of PTGS1 in breast carcinomas
compared to normal tissue is expected from current
knowledge. Several studies have suggested that PTGS1
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[37-41]. The gene has also previously been found over-
expressed in tumors compared with tumor adjacent nor-
mal tissue [42]. There has been large amount of
research on PTGS2 in relation to cancer, indicating a
role in carcinogenesis. The probes for PTGS2 were fil-
tered out due to too many missing values and were not
included in the analysis. Hence, this study lacks infor-
mation about the role of PTGS2-expression in relation
to serum estradiol levels.
TLN2 is less known and less studied than Talin 1
(TLN1). Both talins are believed to connect integrins to
the actin cytoskeleton and are involved in integrin-asso-
ciated cell adhesion [43,44]. TLN2 is located on chromo-
some 15q15-21, close to CYP19A1 coding for aromatase.
A study on aromatase-excess syndrome found that cer-
tain minor chromosomal rearrangements may cause
cryptic transcription of the CYP19A1 gene through the
TLN2-promoter [45]. We found that TLN2 was up-regu-
lated in breasts of healthy women with high levels of
serum estradiol. This could indicate an activation of cell
adhesion. This gene was the only gene significantly up-
regulated according to serum estradiol in normal breast
tissue of premenopausal women. The down-regulation
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Figure 1 Simplified illustration of the cellular mechanisms of action of SCGB3A1. SCGB3A1 inhibits the phosphorylation of Akt leading to
reduced cell cycle division and increased apoptosis. Molecules in red are increased/stimulated as result of SCGB3A1-action, whereas molecules in
blue are decreased/inhibited.
Arachidonic acid
PGE2
PTGS1
CYP19A1
Testosterone Estradiol
Androstendione Estrone
17EHSD1
Figure 2 Schematic illustration of mechanism of action of
PTGS1. PTGS1 induces PGE2-production. PGE2 increases the
expression of aromatase (CYP19A1) which in turn converts
androgens to estrogens in adipose tissue. 17bHSD1 = 17b-
hydroxysteroid dehydrogenase.
Haakensen et al. BMC Cancer 2011, 11:332
http://www.biomedcentral.com/1471-2407/11/332
Page 7 of 11observed in breast cancers compared with normal breast
tissue indicates a loss of cell adhesion. The expression
of the gene is lower in DCIS than in invasive carcino-
mas, which is contrary to expected, but the data set is
small.
A previous study report on the gene expression in
normal human breast tissue transplanted into two
groups of athymic mice treated with different levels of
estradiol [17]. Neither SCGB3A1, TLN2 nor PTGS1 was
significantly differentially expressed in their study. They
did, however, identify many of the genes found to be
significantly differentially expressed according to serum
estradiol in breast carcinomas in the current study, such
as AREG, GREB1, TFF1 and TFF3. Going back to our
normal samples, we see that several of their genes
(including AREG, GREB1, TFF1 and TFF3, GATA3 and
two SERPIN-genes) are differentially expressed in our
normal breast tissue, but did not reach statistical signifi-
cance (Additional file 4).
The differences observed between our study and that of
Wilson and colleagues may be due to chance and due to
the presence of different residual confounding in the two
studies. Wilson and colleagues studied the effects of estra-
diol treatment, which may act differently upon the breast
tissue than endogenous estradiol. Normal human breast
tissue transplanted into mice may react differently to vary-
ing levels of estradiol than it does in its natural milieu in
humans. The genes that were significant in the Wilson-
study and differentially expressed but not significant in
our study (eg: AREG, GREB1, TFF1, TFF3 and GATA3)
may be associated with serum estradiol levels in normal
tissues as well as in tumor tissues where we and others
have observed significant associations. Our study is the
first study to identify the expression of SCGB3A1, TLN2
and PTGS1 in normal breast tissue to be significantly asso-
ciated with serum estradiol levels. These findings are bio-
logically reasonable and may have been missed in previous
studies due to lack of representative study material.
Serum estradiol associated with mammographic density
in healthy women
Serum estradiol levels were independently associated
with mammographic density controlling for age, BMI
and current use of hormone therapy, and the magnitude
of the association was substantial (Table 3). The high
beta-value in the regression equation implies a large
magnitude of impact which supports the hypothesis that
high serum estradiol levels increases mammographic
density with both statistical and biological significance.
Gene expression in breast carcinomas according to serum
estradiol levels
The expression of genes found to be differentially
expressed in normal breast tissue according to serum
estradiol levels was examined in breast carcinomas. We
found that the expression was all opposite of that in
normal breast tissue from women with high serum
estrogen (Table 1). This may be due to lack of negative
feedback of growth regulation in breast tumors. In
breast cancer cell lines, estrogen induced up-regulation
of positive proliferation regulators and down-regulation
of anti-proliferative and pro-apoptotic genes, resulting
in a net positive proliferative drive [46]. This is in line
with our findings. In normal breast tissue from women
with high serum estradiol, SCGB3A1,w h i c hr e g u l a t e
proliferation negatively, and TLN2, which prevents inva-
sion, are up-regulated. PTGS1, which induce local pro-
duction of estradiol-stimulated proliferation, is down-
regulated. All three genes are expressed to maintain
control and regulation of the epithelial cells. In breast
cancers the expression of these genes favors growth,
migration and proliferation. This supports the hypoth-
esis that high serum estradiol increases the proliferative
pressure in normal breasts, which leads to an activation
of mechanisms counter-acting this proliferative pressure.
In carcinomas, growth regulation is lost, and these hor-
mone-related growth-promoting mechanisms are turned
on.
Interestingly, both AREG and GREB1 were up-regu-
lated in ER+ breast carcinomas of younger (< 45 years)
compared with older (> 70 years) women in a previous
publication [47]. The increased expression of these
genes was proposed as a mechanism responsible for the
observed increase in proliferation seen in the tumors of
younger compared with older women [47].
The genes differentially expressed according to serum
estradiol levels in tumors confirmed many of the find-
ings from the Dunbier-study of ER+ tumors [10]. The
previously published list of genes positively correlated
with serum estradiol included TFF-genes and GREB1.
These genes were also found significant in the analysis
of all tumors in this study, although TFF1 and TFF3 did
not reach statistical significance (Table 4). In addition to
the previously published genes, we identified the gene
AREG, an EGFR-ligand essential for breast development,
as up-regulated in tumors from patients with high
serum estradiol.
GREB1 is previously found to be an important estro-
gen-induced stimulator of growth in ER+ breast cancer
cell lines [48]. AREG binds to and stimulates EGFR and
hence epithelial cell growth. The up-regulation of these
two genes in breast carcinomas of women with high
estradiol levels may indicate a loss of regulation of
growth associated with cancer development. This corre-
sponds well with the interpretation of our findings in
normal breast tissue referred above and confirms the
results indicated by the cell line studies by Frasor and
colleagues [46]. These two genes are not differentially
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Page 8 of 11expressed between normal breast tissue and breast can-
c e r s .B o t ha r e ,h o w e v e r ,h i g h e re x p r e s s e di nE R +t h a n
ER- breast carcinomas.
Overall strengths and limitations of the study
The currently used method for detection of serum estra-
diol has a limited sensitivity in the lower serum levels
often seen in postmenopausal women. Despite the lim-
ited sample size we found several biologically plausible
associations. However, due to limited power, there may
be other associations that we could not reveal. We have
included women with and without hormone therapy in
the study. There may be differences in action between
endogenous and exogenous estradiol that will not be
revealed in this study.
One important strength of this study is the unique
material with normal human tissue in its natural mileu,
not influenced by an adjacent tumor [49-51] or by an
adipose-dominated biology that may bias the study of
reduction mammoplasties.
Conclusions
In conclusion we report a list of genes whose expression is
associated with serum estradiol levels. This list includes
genes with known relation to estradiol-signaling, mam-
mary proliferation and breast carcinogenesis. All these
genes were expressed differently in tumor and normal
breast tissue. The gene expression in tumors resembled
that in normal breast tissue from women with low serum
estradiol. Associations between serum estradiol and the
expression in breast carcinomas confirmed previous find-
ings and revealed new associations. The comparison of
results between normal breast tissue from healthy women
and breast carcinomas indicate the difference in biological
impact of estradiol in normal and cancerous breast tissue.
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